Zhu Mingzhe, Li Meng, Zhou Wenjun, Ge Guangbo, Zhang Li, Ji Guang
Institute of Digestive Diseases, China-Canada Center of Research for Digestive Diseases (ccCRDD), Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
School of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Pharmacol. 2020 May 12;11:671. doi: 10.3389/fphar.2020.00671. eCollection 2020.
Qianggan formula, a designed prescription according to the Traditional Chinese Medicine (TCM) theory, is widely used in treating chronic liver diseases, and indicated to prevent blood glucose increase in patients unknown mechanisms. To unravel the effects and underlying mechanisms of Qianggan formula on hyperglycemia, we administrated Qianggan extract to high fat and high sucrose (HFHS) diet rats. Results showed that four-week Qianggan extract intervention significantly decreased serum fasting blood glucose, hemoglobin A1c, and liver glycogen levels. Gas chromatography-mass spectrometry (GC-MS) approach was employed to explore metabolomic profiles in liver and fecal samples. By multivariate and univariate statistical analysis (variable importance of projection value > 1 and value < 0.05), 44 metabolites (18 in liver and 30 in feces) were identified as significantly different. Hierarchical cluster analysis revealed that most differential metabolites had opposite patterns between pair-wise groups. Qianggan extract restored the diet induced metabolite perturbations. Metabolite sets enrichment and pathway enrichment analysis revealed that the affected metabolites were mainly enriched in glycometabolism pathways such as glycolysis/gluconeogenesis, pentose phosphate pathway, fructose, and mannose metabolism. By compound-reaction-enzyme-gene network analysis, batches of genes (e.g, ) or enzymes (e.g. hexokinase and glucokinase) related to metabolites in enriched pathways were obtained. Our findings demonstrated that Qianggan extract alleviated hyperglycemia, and the effects might be partially due to the regulation of glycometabolism related pathways.
强肝方是根据中医理论设计的方剂,广泛用于治疗慢性肝病,并被证明可预防患者血糖升高,但其作用机制尚不清楚。为了揭示强肝方对高血糖的影响及其潜在机制,我们将强肝提取物给予高脂高糖(HFHS)饮食的大鼠。结果表明,四周的强肝提取物干预显著降低了血清空腹血糖、糖化血红蛋白和肝糖原水平。采用气相色谱-质谱联用(GC-MS)方法探索肝脏和粪便样本中的代谢组学特征。通过多变量和单变量统计分析(投影变量重要性值>1且P值<0.05),鉴定出44种代谢物(肝脏中18种,粪便中30种)有显著差异。层次聚类分析表明,大多数差异代谢物在两两分组之间具有相反的模式。强肝提取物恢复了饮食诱导的代谢物扰动。代谢物集富集和通路富集分析表明,受影响的代谢物主要富集在糖代谢途径中,如糖酵解/糖异生、磷酸戊糖途径、果糖和甘露糖代谢。通过化合物-反应-酶-基因网络分析,获得了与富集通路中代谢物相关的一批基因(如……)或酶(如己糖激酶和葡萄糖激酶)。我们的研究结果表明,强肝提取物可缓解高血糖,其作用可能部分归因于对糖代谢相关途径的调节。